ClinicalTrials.gg
CompletedNCT07341373Updated Nov 4, 2026

A Single Bolus, 12-hour Euglycemic Clamp Study of the Safety, Pharmacokinetics (PK) and Glucodynamics (GD) of Intraperitoneal (IP) Portal Insulin U-500

A Phase 1 interventional study of Portal Insulin U-500 and Portal Insulin U-500 in Type 1 Diabetes, sponsored by Portal Diabetes, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Portal Diabetes, Inc. · Phase 1, Interventional, and Treatment

How we know

Updated Nov 4, 2026Now CompletedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 190 open to participants now, 257 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.

Enrollment
748th of 1,242
29 · median 40
Started
2026
with 61 others
Phase 1
147 of 1,458
11 open now
Registered
1,405th of 1,458
by date

Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 748th largest by enrollment of the 1,242 interventional ones that give a count, is one of 62 that started in 2026, is one of 147 in phase 1, and was the 1,405th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

190 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:

185 more — sign in →

All 190 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to assess the safety of a new U500 insulin formulation and to determine how rapidly it is absorbed and how long it takes to act when administered intraperitoneally. The trial will be conducted in people with Type 1 Diabetes. The main questions it aims to answer are:

Is the drug safe and tolerable when administered intraperitoneally? How fast is it absorbed, and how long does it take to act? Researchers will compare the investigational product (PI-U500) with Humulin R U500 administered intraperitoneally and Lyumjev U100 administered subcutaneously.

Participants will undergo a 12-hour clamp procedure in which their blood glucose will be maintained stable via glucose infusion at variable rates after a single intraperitoneal injection of the insulin formulation.

03

Conditions studied

  • Type 1 Diabetes

Keywords

  • Type 1 Diabetes
  • Insulin
  • Intraperitoneal
  • Euglycemic Clamp
  • Diabetes Mellitus
  • Human Insulin
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who meet all the following criteria at Screening will be included in the study:

    1. Subjects ≥18 to ≤60 years of age at the time of signing the .
    2. Subjects diagnosed with T1DM for at least 12 months.
    3. Subjects who have been using an approved insulin pump or use MDI with basal and bolus insulin (stable use for 3 months).
    4. Fasting C-peptide concentration of ≤0.3 nmol/L (0.9061 ng/ml), assessed at a plasma glucose concentration >90 mg/dL. (If necessary, the subject may consume carbohydrates to raise BG over 90 mg/dL as measured by YSI (glucose analyzer) prior to drawing blood for C-peptide. This may be repeated as needed to ensure C-peptide is assessed when plasma glucose concentration is >90 mg/dL).
    5. concentration of ≤8.5%.
    6. (BMI) within the range ≥18.5 to ≤30.0 kg/m2.
    7. Weight ≥ 50 kg.
    8. Female subjects must be non-pregnant and non-lactating and (no menses >12 months); postmenopausal status will be confirmed through testing of follicle-stimulating hormone (FSH) levels at Screening for all female subjects.
    9. Male subjects must be surgically sterile, abstinent or if engaged in sexual relations of , the subject and his partner must be using acceptable methods of .
    10. Has venous access sufficient to allow for blood sampling.
    11. Capable of giving signed informed consent and willing to follow study procedures and commitment to the study duration.

Exclusion criteria

Exclusion Criteria:

  • Subjects who meet any of the following criteria will be excluded from participating in the study:

    1. A subject who has proliferative retinopathy or maculopathy (based on records/documentation of ophthalmologic exam within 18 months of Screening or ophthalmologic exam during Screening), severe gastroparesis, and/or severe neuropathy, in particular autonomic neuropathy, as judged by the Investigator.
    2. History of ≥2 episodes of severe hypoglycemia (as defined per ADA criteria) or ≥1 episodes of diabetic ketoacidosis or emergency room visits for uncontrolled diabetes leading to hospitalization within 6 months prior to Screening.
    3. Subject is not able to avoid major dietary changes for the duration of the study.
    4. Systolic blood pressure >150 mm Hg and/or diastolic blood pressure >90 mm Hg at Screening. Treatment with no more than 2 antihypertensive medications must be with stable doses for at least 3 months prior to Screening.
    5. Current use of any drugs as listed in the table of prohibited medications.
    6. History of any major surgery within 6 months prior to Screening.
    7. History of any serious allergic adverse reaction or to any of the product components.
    8. History of renal disease or abnormal kidney function tests at Screening ( \<60 mL/min/1.73m2 as estimated using the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]).
    9. Triglycerides >500 mg/dL at Screening.
    10. abnormal hematology or biochemistry screening tests. Subjects may have these labs be redrawn once on a separate day.
    11. Any history of heart disease, defined as symptomatic heart failure ( class III or IV), myocardial infarction, coronary artery bypass graft surgery, or angioplasty, unstable angina requiring medication, , cerebral infarct, or cerebral hemorrhage.
    12. Presence of clinically significant physical, laboratory, or findings (eg, >450 msec for males, QTcF >470 msec for females) at Screening that, in the opinion of the Investigator, may interfere with any aspect of study conduct or interpretation of results.
    13. History or presence of malignant neoplasms within the past 5 years prior to the day of Screening. Basal and squamous cell skin cancer and any in-situ carcinomas are allowed.
    14. Clinically significant concomitant disease including cardiovascular, renal, hepatic, respiratory, gastrointestinal, hematological, dermatological, neurological, psychiatric, systemic or infections disease as judged by the Investigator.
    15. Personal or family history of hypercoagulability or thromboembolic disease.
    16. History of any active infection, other than mild viral illness within 30 days prior to dosing as judged by the Investigator.
    17. Administration of any vaccinations in the 2 weeks prior to admission to the clinic.
    18. History of alcohol abuse as judged by the Investigator within approximately 1 year or consuming >2 standard drinks on average per day in men, and >1 standard drinks on average per day in women, and/or positive alcohol breath test at Screening or upon clinic admission. (One drink is defined as 12 fluid ounces of regular beer [5% alcohol], 5 fluid ounces of wine [12% alcohol], or 1.5 fluid ounces of 80 proof [40% alcohol] distilled spirits.)
    19. History of illicit/recreational drug abuse within approximately 1 year as judged by the Investigator. Frequent use of marijuana or other tetrahydrocannabinol (THC) products within 6 weeks, or clinically under the effect at Screening or upon clinic admission, as per Investigator evaluation or a positive urine drug test at Screening or upon clinic admission.
    20. Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day); or non- or occasional smoker who is not able or willing to refrain from smoking and use of nicotine gum or transdermal nicotine patches during the inpatient period.
    21. Known history or positive test of surface antigen (HBsAg), antibody test (anti-HCV), or type 1 (HIV-1) or 2 (HIV-2) antibody at Screening.
    22. Existence of any surgical or medical condition that, in the judgment of the Investigator, might interfere with the absorption, distribution or metabolism of the drugs or the tolerability/safety measurements.
    23. Any subject who, per the opinion of the Investigator, will not make a good study subject relative to mental disorder, history of poor treatment adherence, etc.
    24. Participation in an study within 30 days prior to dosing or within 5 half-lives of the last dose of study drug whichever is longer.
    25. Donation or loss of >500 mL of blood or blood product within 56 days of Screening.
    26. Poor venous access as judged by the study team.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Part A, Group 1, Single Ascending Dose

    Participants will receive PI-U500 intraperitoneally at 0.1 U/kg, then 0.2 U/kg and lastly 0.3 U/kg

    Drug: Portal Insulin U-500

  • Other
    Part B, Group 2

    A three-way crossover where participants will receive 0.1 U/kg of PI-U500, followed by 0.2 U/kg of Humulin R U500 (Active Control), and finally 0.2 U/kg of PI-U500. All administered intraperitoneally.

    Drug: Portal Insulin U-500 · Drug: Humulin R U-500

  • Other
    Part B, Group 3

    A three-way crossover where participants will receive 0.1 U/kg of PI-U500, followed by 0.2 U/kg of Humulin R U500 (Active Control), and finally 0.3 U/kg of PI-U500. All administered intraperitoneally.

    Drug: Portal Insulin U-500 · Drug: Humulin R U-500

  • Other
    Part B, Group 4

    A three-way crossover where participants will receive 0.2 U/kg of Lyumjev U-100 (Active Control) subcutaneously, followed by 0.2 U/kg of PI-U500 intraperitoneally, and finally 0.3 U/kg of PI-U500, also intraperitoneally.

    Drug: Portal Insulin U-500 · Drug: Lyumjev U-100 Insulin

  • Other
    Part B, Group 5

    A two-way crossover where participants will receive 0.2 U/kg of Lyumjev U-100 (Active Control) subcutaneously, followed by 0.2 U/kg of PI-U500 intraperitoneally.

    Drug: Portal Insulin U-500 · Drug: Lyumjev U-100 Insulin

  • Other
    Part B, Group 6

    A three-way crossover where participants will receive 0.2 U/kg of each of the drugs sequentially, but the order will be randomized into three options: * Option 1: 0.2 U/kg of Lyumjev U-100 (Active Control) subcutaneously, followed by 0.2 U/kg of Humulin R U500 (Active Control) intraperitoneally, and finally 0.2 U/kg of PI-U500 intraperitoneally. * Option 2: 0.2 U/kg of Humulin R U500 (Active Control) intraperitoneally , followed by 0.2 U/kg of PI-U500 intraperitoneally, and finally 0.2 U/kg of Lyumjev U-100 (Active Control) subcutaneously. * Option 3: 0.2 U/kg of PI-U500 intraperitoneally , followed by 0.2 U/kg of Lyumjev U-100 (Active Control) subcutaneously, and finally 0.2 U/kg of Humulin R U500 (Active Control) intraperitoneally.

    Drug: Portal Insulin U-500 · Drug: Humulin R U-500 · Drug: Lyumjev U-100 Insulin

Interventions

  • DrugPortal Insulin U-500

    Intraperitoneal delivery of a single dose at 0.1 U/kg during an euglycemic clamp

    Also known as: PI-U500

  • DrugPortal Insulin U-500

    Intraperitoneal delivery of a single dose at 0.2 U/kg during an euglycemic clamp

    Also known as: PI-U500

  • DrugPortal Insulin U-500

    Intraperitoneal delivery of a single dose at 0.3 U/kg during an euglycemic clamp

    Also known as: PI-U500

  • DrugInsulinStudies of InsulinInsulin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intraperitoneal delivery of a single dose at 0.2 U/kg during an euglycemic clamp

  • DrugLyumjev U-100 Insulin

    Subcutaneous delivery of a single dose at 0.2 U/kg during an euglycemic clamp

06

What researchers measure

Primary outcomes

  1. Safety: Incidence of adverse events

    Time frame: From enrollment until the follow-up visit, an average of 2 months

  2. Safety: Change from baseline in systolic and diastolic blood pressure

    Time frame: Will be measured at 2 times, first within 4 hours before drug administration (Pre-clamp) and then after 12 hours of drug administration (post-clamp)

  3. Safety: Change from baseline in temperature

    Time frame: Will be measured at 2 times, first within 4 hours before drug administration (Pre-clamp) and then after 12 hours of drug administration (post-clamp)

  4. Safety: Change from baseline in respiratory rate

    Time frame: Will be measured at 2 times, first within 4 hours before drug administration (Pre-clamp) and then after 12 hours of drug administration (post-clamp)

  5. Safety: Change from baseline in heart rate

    Time frame: Will be measured at 2 times, first within 4 hours before drug administration (Pre-clamp) and then after 12 hours of drug administration (post-clamp)

  6. Safety: Change from baseline in 12-lead electrocardiogram (ECG) parameters

    The following parameters will be recorded from the subject's ECG trace as calculated by the machine algorithm: heart rate, QT interval, PR interval, QRS interval, RR interval, and QTc (corrected) using the Fridericia correction (QTcF = QT ÷ cube root of the R-R interval \[where R-R is the duration of the entire cardiac cycle\]).

    Time frame: Pre-dose and after the end of PK-sampling (720 minutes post-dose)

  7. Safety: Incidence and severity of clinical findings on physical examination

    Time frame: Pre-dose and after the end of PK-sampling (720 minutes post-dose)

  8. Tolerability: Pain assessments per Visual Analogue Scale (VAS)

    VAS assessment will target the assessment of abdominal pain. The scale will go from 0 to 10, with 10 being the maximum pain.

    Time frame: 10 min and 1 hour post-dosing

  9. Tolerability: Change in Interleukin 6 [IL-6] levels

    Time frame: Blood samples will be taken immediately before dosing, 2 hours after dosing, and with the last PK sample (720 minutes after dosing)

  10. Tolerability: Change in tumor necrosis factor [TNF-α] levels

    Time frame: Blood samples will be taken immediately before dosing, 2 hours after dosing, and with the last PK sample (720 minutes after dosing)

  11. Tolerability: Change in high sensitivity C-reactive protein [hsCRP] levels

    Time frame: Blood samples will be taken immediately before dosing, 2 hours after dosing, and with the last PK sample (720 minutes after dosing)

  12. Pharmacokinetic: Area under the insulin concentration-time curve (AUC)

    For the duration of the euglycemic clamp

    Time frame: From the time of dose (time 0) until 12 hours post-dose (AUCIns,0-12h)

  13. Pharmacokinetic: Maximum insulin concentration (Cmax)

    Time frame: Over 12 hours post-dosing

  14. Pharmacokinetic: Time to maximum insulin concentration (Tmax)

    Time frame: Over 12 hours post-dosing

  15. Glucodynamic: Area under the glucose infusion rate (GIR) time curve

    Time frame: From the time of dose (time 0) until 12 hours post-dose (AUCGIR,0-12h)

  16. Glucodynamic: Maximum GIR (GIRmax)

    Time frame: Over 12 hours post-dosing

  17. Glucodynamic: Time to maximum GIR (TGIRmax)

    Time frame: Over 12 hours post-dosing

Secondary outcomes

  1. Pharmacokinetic: Area under the partial insulin concentration-time curves (AUC) in time intervals

    Time frame: From 0 to 15 minutes (AUCIns,0-15 min), from 0-30 minutes (AUCIns,0-30 min) and from 3 hours to end (AUCIns,3h-end)

  2. Pharmacokinetic: Time to half-maximum insulin concentration before Cmax (t50%-INS (early))

    Time frame: Over 12 hour post-dosing

  3. Pharmacokinetic: Time to half-maximum insulin concentration after Cmax (t50%-INS (late))

    Time frame: Over 12 hours post-dosing

  4. Pharmacokinetic: Onset of appearance

    Defined as time from study drug administration until the first time insulin concentrations were equal to or higher than the lower limit of quantification

    Time frame: Over 12 hours post-dosing

  5. Glucodynamic: Area under GIR time curve in time intervals

    Time frame: From 0-30 minutes (AUCGIR,0-30 min), from 0 to 1 hour (AUCGIR,0-1h), from 4 hours to end (AUCGIR,4h-end), from 0 to 6 hours (AUCGIR,0-6h) and from 0 to end (AUCGIR,0-end)

  6. Glucodynamic: Time to half-maximum GIR before GIRmax (t50%-GIR (early))

    Time frame: Over 12 hours post-dosing

  7. Glucodynamic: Time to half-maximum GIR after GIRmax (t50%-GIR (late))

    Time frame: Over 12 hours post-dosing

07

Study locations

1 site
  • ProSciento, Inc.
    Chula Vista, California 91911, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2026 to primary completion in Sep 2026, 7 months.

Of 97 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 7 months is close to that.

Counting every sponsor, half of 153 studies reached it within 12 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2025
First posted
Jan 14, 2026
StartActual
Feb 10, 2026
Primary completionActual
Sep 30, 2026
CompletionActual
Sep 30, 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 4, 2026
Enrollment
25 (estimated)→29 (actual)
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Recruiting→Completed
    Enrollment 25 (estimated)→29 (actual)
    + 3 other changes: date precision, site details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07341373
Lead sponsor
Portal Diabetes, Inc.
Responsible party
Sponsor
First posted
Jan 14, 2026
Start date
Feb 10, 2026
Primary completion
Sep 30, 2026
Completion
Sep 30, 2026
Last update
Nov 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion